A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Conditions
Achondroplasia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Lundquist Institute for Biomedical Innovation, Torrance, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Nemours Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Uncommon Cures, Chevy Chase, Maryland, United States
University of Missouri, Columbia, Missouri, United States
Washington University, St Louis, Missouri, United States
Duke University Hospital, Durham, North Carolina, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Children's Medical Center, Dallas, Dallas, Texas, United States
University of Texas Health Science Center Medical School at Houston, Houston, Texas, United States
University of Wisconsin-Madison, Madison, Wisconsin, United States
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Royal Children's Hospital, Parkville, Victoria, Australia
Women's and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada
Contact: Study coordinator (Lee-Ann Carroll) · lee-ann.carroll@albertahealthservices.ca · (780) 248-5616Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
The Hospital for Sick Children, Toronto, Ontario, Canada
Unidad de Cirugía Artroscópica (MIKS Hospital), Vitoria-Gasteiz, Alava, Spain
Astrid Lindgren Children's Hospital (Karolinska University Hospital), Stockholm, Sweden
Study leads
Doug Warner, MD
Study Chair
Tyra Biosciences